Pharmaceutical firm Mankind Pharma Ltd on Thursday (July 31) reported an 18.1% year-on-year (YoY) decline in net profit at ₹444.6 crore for the first quarter, down from ₹543 crore in Q1FY25.
However, revenue from operations surged 24.5% to ₹3,570 crore against ₹2,868 crore year-on-year.
At the operating level, EBITDA increased 26% to ₹847.6 crore in the first quarter of this fiscal over ₹672.6 crore in prior-year period. EBITDA margin improved slightly to 23.7% from 23.4%.
Also Read: Mankind Pharma shares extend gains over the last month after Jefferies raises target
The company reported a 20.1% YoY fall in diluted earnings per share (EPS) to ₹10.6 for Q1FY26. Domestic revenue rose 18.9% to ₹3,101 crore, while export revenue surged 81.1% to ₹469 crore, aided by the consolidation of BSV and growth in the base business.
Mankind’s market share increased from 4.8% in March 2025 to 4.9% in June 2025, reflecting its continued outperformance relative to the Indian pharmaceutical market (IPM). For Q1FY26, secondary sales grew by 9.2% compared to IPM’s 8.6%.
Volume growth stood at 2.5% versus IPM’s 1.4%, marking a 1.8x outperformance. Respiratory and anti-infective therapies recorded strong growth of 17.8% and 9.1%, respectively, outperforming IPM by 1.5x and 1.6x. In the chronic segment, the company continued its outperformance, with 1.4x growth over IPM; cardiac and anti-diabetic therapies grew 1.5x and 1.6x faster than the IPM average.
Also Read: Mankind Pharma Q4 Results: Profit drops, revenue surges 27% on-year
The consumer healthcare business registered a robust 15 % YoY growth in Q1FY26, supported by consistent performance across all key brands. Modern trade and e-commerce channels contributed 11% of revenue during the quarter, up from 9% in Q1FY25, backed by nearly 50% growth. Notable secondary sales growth was recorded for brands such as Gas-o-fast (36%), Manforce Condoms (18%), HealthOk (15%), and Preganews (12%).
In the exports segment, revenue grew 81.1% over last year, primarily due to the BSV consolidation and growth in the base business. Mankind (excluding BSV) launched one new product in Q1FY26 in the US market, bringing the total number of products launched in the region to 45.
The results came after the close of the market hours. Shares of Mankind Pharma Ltd ended at ₹2,552.90, down by ₹22.10 or 0.86%, on the BSE.
Also Read: Mankind Pharma completes amalgamation of three subsidiaries
